Viewing nowDonghwa Memantine Tablets (Memantine Hydrochloride)
Memantine Hydrochloride 10mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.

MFDS item code 200500765 · Notified 2005.08.31 · Insurance code 642700420
Treatment of moderate to severe Alzheimer's disease
This medication is used for the treatment of moderate to severe Alzheimer's disease. It helps improve cognitive function impairment caused by Alzheimer's disease, thereby enhancing the ability of patients to carry out daily activities. This can alleviate symptoms such as memory decline and confusion, and improve the overall quality of life. It is important to take this medication consistently according to a doctor's instructions, as it is effective for symptom management.
Treatment must be initiated by a physician experienced in the diagnosis and treatment of Alzheimer's dementia, and only if a caregiver can periodically verify that the patient is taking the medication. Diagnosis should be made according to currently accepted guidelines. The clinical benefit of this drug and the patient's tolerability of treatment should be reassessed periodically. This drug may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows, until the maintenance dose is reached. Week 1 (days 1–7): Administer 5mg daily for 7 days. Week 2 (days 8–14): Administer 10mg daily (5mg twice daily) for 7 days. Week 3 (days 15–21): Administer 15mg daily (10mg in the morning and 5mg in the evening) for 7 days. From week 4: Administer 20mg daily (10mg twice daily). Maintenance dose: The recommended maintenance dose is 20mg daily (10mg twice daily). 2. Elderly patients: Based on clinical data, the recommended dose for elderly patients aged 65 years or older is 20mg daily (10mg twice daily). 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-50 mL/min), the daily dose should be reduced to 10mg. If well tolerated after at least 7 days of treatment, the dose may be increased to 20mg daily according to the standard dose-escalation schedule. In patients with severe renal impairment (creatinine clearance 5-30 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment: No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this drug.
This medicine should not be used in patients with an allergy to any of its components. It is also advisable not to administer it to patients with severely impaired liver function or extremely reduced kidney function. Special care should be taken for patients with epilepsy or those who have previously experienced seizures or are prone to seizures. Combination with other medications that have similar effects may increase the risk of central nervous system side effects, thus concurrent use should be avoided. Caution should be exercised when administering to patients with conditions that may alter urinary acidity, heart diseases, or uncontrolled hypertension. During treatment with this medication, side effects such as dizziness, headache, constipation, drowsiness, and hypertension may occur, and if symptoms are severe, consultation with a physician is advised. As this medication may interact with other drugs, it is essential to inform healthcare professionals if taking other medications. Women who are pregnant or may become pregnant should carefully consider the risks and benefits of taking this medication, and breastfeeding mothers are advised to discontinue nursing. It is recommended not to use this medication in children or adolescents under 18, as its safety and efficacy have not been established. In case of overdose, symptoms such as confusion, drowsiness, dizziness, and vomiting may occur, requiring immediate medical attention. This medication may affect the central nervous system and impair driving or machinery operation capabilities, so caution is needed when performing such activities. Store out of reach of children and do not transfer the medication to another container as it helps maintain quality.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air exposure, at room temperature between 1°C and 30°C for safety. Storing it this way helps maintain its effectiveness.
White, rectangular film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowMemantine Hydrochloride 10mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.
Memantine Hydrochloride 1g
Solution · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Youngjin Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Unimed Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Myongin Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Jinyang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.